linjc16/ctgov huggingface dataset:
The Analysis of Thyroidectomy and Parathyroidectomy

Study Overview
=================
Brief Summary
-----------------
To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.

Detailed Description
-----------------
Utilizing our institutional database, tissue bank, and electronic medical charts to surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.

Official Title
-----------------
The Analysis of Thyroidectomy and Parathyroidectomy

Conditions
-----------------
Thyroid Diseases, Parathyroid Diseases

Intervention / Treatment
-----------------
* Biological: Thyroid and parathyroid disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age more than 20 years thyroid or parathyroid disorder willing to receive management at National Taiwan University Hospital (NTUH) Exclusion Criteria: age less than 20 years

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Death or live | 1 month | 
| Progression | Recurrence or metastasis | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor growth | Size variation of tumor | 1 cm/month | 
| Life quality | Cosmetic and symptoms, using short-form (SF)-36 and patient satisfaction scale (as tumor volume reduction rate, satisfy as >50%) | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
surgery, ablation, minimal invasive surgery
Articular Sonography: Healthy Subjects Versus Rheumatoid Arthritis Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish the normality of sonographic synovial measures in joints more affected in rheumatoid arthritis patients and establish, in those joints, a sonographic value of synovium predictive of rheumatoid arthritis.

Detailed Description
-----------------
Rheumatoid arthritis (RA) is a chronic inflammatory, systemic and auto-imune disorder affecting primarily the joints. In RA, inflammatory synovium causes destruction of cartilage, erosion of the adjacent bone and ultimately loss of function of the affected joint. Newer imaging techniques, such as ultrasound (US), have shown promise in evaluation of RA. Many US scoring system have been used to classify and quantify the synovium, effusion, erosion and cartilage for assessing and monitoring AR. However, its use is considered problematical because there are very few data on normal joints and, at this point, there is no clear definition of excess amount of synovium in normal people.

Official Title
-----------------
Articular Sonography: Findings in Healthy Subjects Compared With Rheumatoid Arthritis Patients

Conditions
-----------------
Disorders of Synovium, Multiple Sites, Disorders of Subchondral Bone, Multiple Sites, Disorders of Cartilage, Hand Joints, Arthritis, Rheumatoid, Healthy People

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no articular disease (healthy group) establish rheumatoid arthritis (RA group) Exclusion Criteria: diabetes hypothyroidism- hemophilia pregnancy previous septic arthritis previous articular surgery symptomatic osteoarthritis no superimposed collagenoses (RA group)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy<br>normal, healthy people | |
| RA<br>rheumatoid arthritis patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Using Red Djulis Products Can Improve Skin Conditions

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Using red djulis products can improve skin conditions

Official Title
-----------------
Using Red Djulis Products Can Improve Skin Conditions

Conditions
-----------------
Skin Condition

Intervention / Treatment
-----------------
* Dietary Supplement: placebo group
* Dietary Supplement: red djulis drinks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dry skin Rough skin Large pores Dark yellow complexion Sagging skin Exclusion Criteria: Skin disorders Liver diseases Kidney diseases Allergy to cosmetics, drugs, or foods Pregnant and lactating women People who had any cosmetic procedures before 4 weeks of the study Area of facial spot over 3 cm2 Vegan People who took collagen supplements in the past 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo group<br>subjects drank 50 ml , 1 bottle a day for 8 week | Dietary Supplement: placebo group<br>* subjects drank 50 ml , 1 bottle a day for 8 week<br>|
| Experimental: red djulis drinks<br>subjects drank 50 ml , 1 bottle a day for 8 week | Dietary Supplement: red djulis drinks<br>* subjects drank 50 ml , 1 bottle a day for 8 week<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin moisture | using corneometer CM825 to examine skin moisture (The higher the value, the more water content, C.U., corneometer units ). subjects drank 50 ml after meal | up to 8 week | 
| skin elasticity | using cutometer dual MPA580 to examine skin elasticity (The closer the R2 value is to 1, the better the elasticity and no unit) | up to 8 week | 
| skin gloss | using probe system GL2000 & MPA10 to examine skin gloss (The higher the value, the higher the gloss, no unit) | up to 8 week | 
| skin spot | usig VISIA-CR to examine skin spot (The higher the value, the larger the pore area, mm2) | up to 8 week | 
| skin wrinkle | using VISIOSCAN-VC20 to examine skin wrinkle (The higher the value, the more wrinkles, surface evaluation of wrinkles, SEW) | up to 8 week |
Experiences With a Genetic Test for Personalized Nutrition Test for Personalized Nutrition

Study Overview
=================
Brief Summary
-----------------
The investigators will use a web-based survey to collect data on individual attitudes and self-reported health behaviour changes following genetic testing for personalized nutrition. Participants (n=80) are employees of a large multi-national food company's R&D division located in Australia, Switzerland, USA and the UK. They underwent a genetic test for personalized nutrition in March 2015 that was offered at no cost through the company wellness program. A registered dietitian completed a pre-test consultation and disclosed the test results with DNA-based dietary advice. The test provided information on 7 components of diet and additional information on individual risk for gluten intolerance.

Official Title
-----------------
Experiences With a Healthcare Professional-mediated Genetic Test for Personalized Nutrition

Conditions
-----------------
Health Behavior

Intervention / Treatment
-----------------
* Behavioral: Genetic test for personalized nutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Completed a genetic test for personalized nutrition through company wellness program. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Genetic test for personalized nutrition|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health behaviour change | Do individuals self-report beneficial changes to their diets or lifestyle as a result of the DNA-based dietary advice? | 3 months |
Florida Neonatal Neurologic Network

Study Overview
=================
Brief Summary
-----------------
Create a database with selected medical information on infants born with hypoxic-ischemic encephalopathy (HIE). In addition, the following samples will be collected in a bio-repository for future studies: blood, urine, and buccal samples.

Detailed Description
-----------------
The purpose of this study is to create a detailed medical and sample database of infants born with HIE. Both the medical information and the samples are de-identified. Any future studies performed with the data and samples will receive Institutional Review Board (IRB) approval.

Official Title
-----------------
Florida Neonatal Neurologic Network

Conditions
-----------------
Hypoxic-Ischemic Encephalopathy

Intervention / Treatment
-----------------
* Other: Database Entry/Biospecimen Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational Age greater than or equal to 35 weeks gestation Birth weight greater than or equal to 1.8 kg Less than or equal to 6 hours since insult occurred Severe hypoxic-ischemic encepholopathy (HIE) Exclusion Criteria: Presence of lethal chromosomal abnormalities Severe IUGR Significant intracranial hemorrhage with a large intracranial hemorrhage (Grade III or intraparenchymal echodensity (Grade IV))

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 3 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Database Entry/Biospecimen Collection<br>Medical information of infants born with HIE entered into RedCap database. In addition, Blood, urine, buccal samples will be collected. | Other: Database Entry/Biospecimen Collection<br>* blood, urine, buccal samples and medical data collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of blood-based biomarkers of neonatal Hypoxic Ischemic Encephalopathy (HIE) | Measure HIE biomarker levels in blood samples obtained in infants born with HIE. | 2 years |
Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil

Study Overview
=================
Brief Summary
-----------------
Study to investigate the efficacy and safety of Vardenafil

Official Title
-----------------
A Randomised, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy, Safety, and Reliability of 10mg Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Drug: Levitra (Vardenafil, BAY38-9456)
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heterosexual males >/= 18 years old with ED for more than six months Subjects also needed a positive first-time response to a single dose of 10mg vardenafil to be eligible for randomisation Exclusion Criteria: Primary hypoactive sexual desire History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month Nitrate therapy Other exclusion criteria apply according to the Summary of Product Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Levitra (Vardenafil, BAY38-9456)<br>* 10 mg Vardenafil to be taken 1 h prior to sexual attempt<br>|
| Placebo Comparator: Arm 2<br> | Drug: Placebo<br>* Matching placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sexual Encounter Profile question 2 (SEP 2) |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sexual Encounter Profile question 3 (SEP 3) |  | 12 weeks | 
| International Index of Erectile Function (IIEF) - EF (Erectile Function) domain |  | 12 weeks | 
| Safety and Tolerability |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erectile Dysfunction, Vardenafil
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Study Overview
=================
Brief Summary
-----------------
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.

Official Title
-----------------
A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: Octreotide Acetate in Microspheres
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females with type 1 and type 2 diabetes mellitus Moderately severe or severe NPDR or mild PDR in at least one eye: with an Early Treatment Diabetic Retinopathy Study (ETDRS) visual score of > 35 letters; and not previously treated with scatter photocoagulation. HbA1c < 13% at study entry Exclusion Criteria: Condition which could interfere with the assessment of retinopathy progression History of symptomatic gallstones without cholecystectomy Brittle diabetes or history of severe hypoglycemia unawareness Previous treatment with a somatostatin analogue

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Octreotide Acetate in Microspheres<br> | Drug: Octreotide Acetate in Microspheres<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to progression of diabetic retinopathy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to development or progression of macular edema, |  |  | 
| time to moderate vision loss |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic retinopathy, Octreotide Acetate in Microspheres
The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

Detailed Description
-----------------
It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion, and increased inflammatory activity is associated with vascular access failure, cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6 plays an important role in modulating immune response, inhabiting toll-like receptor (TLR) signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients in three-years follow-up.

Official Title
-----------------
The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients: a Cohort Study

Conditions
-----------------
Hemodialysis Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hemodialysis for more than 6 months Exclusion Criteria: patients who received warfarin therapy; patients with chronic infectious disease or acute infection; patients with hemodialysis inadequacy; the age of patients is older than 65 years or younger than 18 years. patients who can not sign an informed consent or disagree to follow up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death | death | 3 years | 
| dialysis complication | vascular access failure, stroke, acute coronary syndrome, heart failure | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemodialysis, Axl, prognosis
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.

Detailed Description
-----------------
A multicenter, randomized, double-blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment.

Official Title
-----------------
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients with COPD and FEV1 <60% of predicted normal and baseline (pre-bronchodilator) FEV1/FVC ratio <70%. Current or ex-smokers with a smoking history of at least 10 pack-years. Exclusion criteria: Diagnosis of other respiratory disorders (including asthma). Requirement for long term oxygen therapy.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality at 3 years |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of moderate and severe COPD exacerbations and health status assessed by the St. George's Respiratory Questionnaire. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mortality, TORCH, SERETIDE, ADVAIR, COPD
Non Contrast MRI in Lower Extremity

Study Overview
=================
Brief Summary
-----------------
We collected retrospectively the non contrast MRI in chia yi memorial hospital for different venous disease of lower extremity morphology and flow ananlysis were done.

Detailed Description
-----------------
Retrospective, analysis of the venous figure by TRANCE MRI no drug/contrast median usage no radiation toxicity the range from the pelvic to the toe

Official Title
-----------------
Non Contrast MRI in Lower Extremity: Role in Varicose Vein , Stasis Ulcer and Obstructive Venous Disease

Conditions
-----------------
Venous Insufficiency of Leg, Venous Leg Ulcer, Venous Occlusion, Contrast Media Reaction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: possible venous disease no contraindication for mri Exclusion Criteria: could not tolerate mri packemaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| image quality | good or artifact | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI, CVS, contrast, reflux, ablation